IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses

• US 7,807,471 B2
• Filed: 06/26/2007
• Issued: 10/05/2010
• Est. Priority Date: 09/24/2004
• Status: Active Grant

• Current Assignee: Centocor Ortho Biotech Incorporated (Johnson & Johnson)
• Original Assignee: Centocor Ortho Biotech Incorporated (Johnson & Johnson)
• Inventors: Luo, Jeffrey (Sinquan), Cunningham, Mark, Benson, Jacqueline
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US11/768,582
• Publication Number:
  US 20080038831A1
• Time in Patent Office: 1,197 Days
• Field of Search: None
• US Class Current: 436/86
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: G01N 33/6869 Interleukin

Abstract

An anti-IL-23 specific human Ig derived protein, isolated nucleic acids that encode at least one anti-IL-23 Ig derived protein, vectors, host cells, transgenic animals or plants, and methods of making and using thereof are useful as therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably binds to one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.

Claims

1. A method of selecting an anti-IL-23 antibody, comprising panning an antibody library with a variant murine p40 subunit of IL-23 and recovering the antibody binding to the variant murine p40subunit of IL-23, wherein the variant murine p40 subunit of IL-23 comprises at least one replacement from the group consisting of:

(i) replacing residues 97 and 98 of the amino acid sequence of SEQ ID NO;

2 with residues 97-101 of the amino acid sequence of SEQ ID NO;

1, (ii) replacing residues 135-142 of the amino acid sequence of SEQ ID NO;

2 with residues 138-145 of the amino acid sequence of SEQ ID NO;

1, and (iii) replacing residues 247-274 of the amino acid sequence of SEQ ID NO;

2 with residues 250-269 of the amino acid sequence of SEQ ID NO;

1.

2. The method of claim 1, wherein the variant murine P40 subunit of IL-23 comprises a replacement of residues 135-142 of the amino acid sequence of SEQ ID NO:

2 with residues 138-145 of the amino acid sequence of SEQ ID NO;

1.

3. The method of claim 1, wherein the variant murine P40 subunit of IL-23 comprises a replacement of residues 97 and 98 of the amino acid sequence of SEQ ID NO:

2 with residues 97-101 of the amino acid sequence of SEQ ID NO;

1.

4. The method of claim 3, wherein the variant murine P40 subunit of IL-23 comprises a replacement of residues 247-274 of the amino acid sequence of SEQ ID NO:

2 with residues 250-269 of the amino acid sequence of SEQ ID NO;

1.

5. The method of claim 1, wherein the variant murine P40 subunit of IL-23 comprises:

(i) a replacement of residues 97 and 98 of the amino acid sequence of SEQ ID NO;

2 with residues 97-101 of the amino acid sequence of SEQ ID NO;

1, (ii) a replacement of residues 135-142 of the amino acid sequence of SEQ ID NO;

2 with residues 138-145 of the amino acid sequence of SEQ ID NO;

1, and (iii) a replacement of residues 247-274 of the amino acid sequence of SEQ ID NO;

2 with residues 250-269 of the amino acid sequence of SEQ ID NO;

1.

6. A method of generating an anti-IL-23 antibody, comprising immunizing an animal producing antibodies with a variant murine p40 subunit of IL-23 and recovering an antibody binding to the variant murine p40 subunit of IL-23, wherein the variant murine p40 subunit of IL-23 comprises at least one replacement from the group consisting of (i) replacing residues 97 and 98 of the amino acid sequence of SEQ ID NO:

2 with residues 97-101 of the amino acid sequence of SEQ ID NO;

1, (ii) replacing residues 135-142 of the amino acid sequence of SEQ ID NO;

2 with residues 138-145 of the amino acid sequence of SEQ ID NO;

1, and (iii) replacing residues 247-274 of the amino acid sequence of SEQ ID NO;

2 with residues 250-269 of the amino acid sequence of SEQ ID NO;

1.

7. The method of claim 6, wherein the variant murine P40 subunit of IL-23 comprises a replacement of residues 135-142 of the amino acid sequence of SEQ ID NO:

2 with residues 138-145 of the amino acid sequence of SEQ ID NO;

1.

8. The method of claim 6, wherein the variant murine P40 subunit of IL-23 comprises a replacement of residues 97 and 98 of the amino acid sequence of SEQ ID NO:

2 with residues 97-101 of the amino acid sequence of SEQ ID NO;

1.

9. The method of claim 6, wherein the variant murine P40 subunit of IL-23 comprises a replacement of residues 247-274 of the amino acid sequence of SEQ ID NO:

2 with residues 250-269 of the amino acid sequence of SEQ ID NO;

1.

10. The method of claim 6, wherein the variant murine p40 subunit of IL-23 comprises:

(i) a replacement of residues 97 and 98 of the amino acid sequence of SEQ ID NO;

2 with residues 97-101 of the amino acid sequence of SEQ ID NO;

1, (ii) a replacement of residues 135-142 of the amino acid sequence of SEQ ID NO;

2 with residues 138-145 of the amino acid sequence of SEQ ID NO;

1, and (iii) a replacement of residues 247-274 of the amino acid sequence of SEQ ID NO;

2 with residues 250-269 of the amino acid sequence of SEQ ID NO;

1.